therapeutics

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025 16:05 ET  | Source: Vera Therapeutics BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc.…

12 hours ago
Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell CarcinomaAriceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma

Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma

October 09, 2025 02:00 ET  | Source: Ariceum Therapeutics Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study…

2 days ago
Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International MarketsHalia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International Markets

Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International Markets

New CSO & GM role underscores Halia's commitment to resilience-based therapeutic development and advances collaboration with the Department of Health…

4 days ago
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 MillionVivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million

Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES…

5 days ago
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

October 05, 2025 09:00 ET  | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…

6 days ago
Spyre Therapeutics Announces Grants of Inducement AwardsSpyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards

October 03, 2025 16:05 ET  | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…

7 days ago
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025 16:01 ET  | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics,…

7 days ago
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025 16:15 ET  | Source: Context Therapeutics Inc. PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.…

1 week ago
Cirrus Therapeutics Raises $11 M Seed Financing to Advance Novel Ocular Gene Therapy to Reverse Underlying Age-Related Cause of Dry AMDCirrus Therapeutics Raises $11 M Seed Financing to Advance Novel Ocular Gene Therapy to Reverse Underlying Age-Related Cause of Dry AMD

Cirrus Therapeutics Raises $11 M Seed Financing to Advance Novel Ocular Gene Therapy to Reverse Underlying Age-Related Cause of Dry AMD

October 02, 2025 10:00 ET  | Source: Cirrus Therapeutics, Inc. Cirrus’ lead program is a novel AAV gene therapy designed…

1 week ago
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual MeetingC4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

September 20, 2025 11:00 ET  | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…

3 weeks ago
Show more Posts